Cite
HARVARD Citation
Janku, F. et al. (n.d.). DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study. European journal of cancer. pp. S4-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Janku, F. et al. (n.d.). DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study. European journal of cancer. pp. S4-. [Online].